Cases with Jay Yepuri, MD, FACG

Aligning patient care with personal risk


Jay Yepuri, MD, FACG has a great view of the gastroenterology landscape. He is a practicing gastroenterologist in the Dallas/Fort Worth area as well as the current ACG Governor for Texas, Vice Chairman of the Clinical Governance Board for GI Alliance, and a member of the Physician Executive Board for GI Alliance.

For patients with Barrett’s esophagus (BE), Dr. Yepuri is a proponent of using endoscopic eradication therapies (EET) for those with a high risk of progression to esophageal cancer. However, those therapies have a small risk of adverse events, so it is important to determine which patients can benefit most from  EET to prevent esophageal cancer.

“The strength TissueCypher offers is the ability to determine, ‘Is it worth putting this patient through the risk of EET, or are we able to do the right thing for the patient by de-escalating from EET to standard surveillance based on guidelines?’”

Dr. Yepuri shared a few cases with us to show how he is leveraging the objective data provided by TissueCypher to make risk-aligned management decisions for patients with Barrett's esophagus. 

See Dr. Yepuri's TissueCypher case studies

  • Confirming low risk of progression in a young female patient

    See how Dr. Yepuri handled the case of a young female patient who received an unexpected diagnosis of Barrett’s esophagus.

    Read more

  • A patient with multiple EGDs and conflicting endoscopic findings

    This case of a 75-year-old female required Dr. Yepuri to weigh multiple conflicting data points to recommend the best care for an anxious patient.

    Read more

  • Downstaging a patient referral for radio-frequency ablation

    This case of a 52-year-old male gives an example of how the decision on whether or not to pursue EET is not always clear.

    Read more

  • The strength TissueCypher offers is the ability to determine, ‘Is it worth putting this patient through the risk of EET, or are we able to do the right thing for the patient by de-escalating from EET to standard surveillance based on guidelines?'"

    Jay Yepuri, MD, FACG